CYP3A5 and ovarian carcinoma: Nonexpressers of CYP3A5 (carriers of CYP3A5*3) in Chinese epithelial ovarian cancer patients were at an increased risk of developing toxicity induced by the combination of paclitaxel/carboplatin (Hu et al., 2016).